BRAF and melanoma: BRAF inhibitor vemurafenib-treated melanoma cells was found to lead to transforming growth factor beta 1 (TGF-β1) release, which increases the deposition of fibronectin, type I collagen, α-smooth muscle actin ‘as well as CAFs [24,25].